Ladenburg analyst Ahu Demir reiterates a Buy rating on Immutep (IMMP) shares after the company entered a second clinical trial agreement with Merck KGaA (MKGAY) and Pfizer (PFE) for a new open-label Phase 1 trial for the combination study of efti and avelumab in up to 30 patients with metastatic urothelial cancer. Demir tells investors in a research note that this is likely more of a commercially strategic decision for avelumab, and is positive for Immutep. The analyst expects to see the topline data analysis from the TACTI-003 study in 1L HNSCC in mid-2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMP:
- Immutep enters into second clinical trial agreement with Merck KGaA
- Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
- Immutep Receives Australian R&D Tax Incentive
- Immutep announces clinical results from Phase II trial of eftilagimod alpha
- Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference